Intravenous and intra-arterial chemotherapy for retinoblastoma: What have we learned?

Current Opinion in Ophthalmology

Volumn 23, Issue 3, 2012, Pages 202-209

  Shields, Carol L ^a   Kaliki, Swathi ^a   Rojanaporn, Duangnate ^a   Al Dahmash, Saad ^a,b   Bianciotto, Carlos G ^a   Shields, Jerry A ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

chemoreduction; intra arterial chemotherapy; retinoblastoma

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; ETOPOSIDE; MELPHALAN; VINCRISTINE;

CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER PATIENT; CANCER RADIOTHERAPY; DISEASE SURVEILLANCE; EXTERNAL BEAM RADIOTHERAPY; FERTILITY; HUMAN; INFERTILITY; INTRAARTERIAL CANCER CHEMOTHERAPY; INTRAVENOUS CANCER CHEMOTHERAPY; LEUKEMIA; LONG TERM CARE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETINOBLASTOMA; REVIEW;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; HUMANS; INFUSIONS, INTRA-ARTERIAL; INFUSIONS, INTRAVENOUS; RETINAL NEOPLASMS; RETINOBLASTOMA;

EID: 84859731305     PISSN: 10408738     EISSN: 15317021     Source Type: Journal    
DOI: 10.1097/ICU.0b013e3283524130     Document Type: Review

References (65)

1. Kivela T. The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death. Br J Ophthalmol 2009; 93:1129-1131.
2. Shields JA, Shields CL. Retinoblastoma. In Shields JA, Shields CL, editors. Intraocular tumors: an atlas and textbook. 2nd ed. Philadelphia, PA: Lippincott Williams Wilkins; 2008. pp. 293-365.
3. Shields JA, Shields CL. Management and prognosis of retinoblastoma. In Shields JA, Shields CL, editors. Intraocular tumors: a text and atlas. Philadelphia: WB Saunders; 1992. pp. 377-392.
4. Broaddus E, Topham A, Singh AD. Survival with retinoblastoma in the USA: 1975-2004. Br J Ophthalmol 2009; 93:24-27.
5. MacCarthy A, Birch JM, Draper GJ, et al. Retinoblastoma: treatment and survival in Great Britain 193 to 2002. Br J Ophthalmol 2009; 93:38-39.
6. Abramson DH, Schefler AC. Update on retinoblastoma. Retina 2004; 24:828.
7. Shields CL, Shields JA. Changing management of retinoblastoma (Editorial). Clin Exper Ophthalmol 2004; 32:345-346. (Pubitemid 39193847)
8. Shields CL, Shields JA. Basic understanding of current classification and management of retinoblastoma. Curr Opin Ophthalmol 2006; 17:228-234. (Pubitemid 44309745)
9. Shields CL, Shields JA. Retinoblastoma management: advances in enucleation, intravenous chemoreduction, and intra-arterial chemotherapy. Curr Opin Ophthalmol 2010; 21:203-212.
10. Wilson MW, Qaddoumi I, Billups C, et al. A clinicopathological correlation of 67 eyes primarily enucleated for advanced intraocular retinoblastoma. Br J Ophthalmol 2011; 95:553-558.
11. Shields CL, Shields JA, Baez K, et al. Optic nerve invasion of retinoblastoma. Metastatic potential and clinical risk factors. Cancer 1994; 73:692-698.
12. Shields CL, Shields JA, Baez K, et al. Choroidal invasion of retinoblastoma. Metastatic potential and clinical risk factors. Br J Ophthalmol 1993; 77:544-548. (Pubitemid 23281450)
13. Uusitalo MS, Van Quill KR, Scott IU, et al. Evaluation of chemoprophylaxis in patients with unilateral retinoblastoma with high-risk features on histopathologic examination. Arch Ophthalmol 2001; 119:41-48. (Pubitemid 32096384)
14. Honavar SG, Singh AD, Shields CL, et al. Postenucleation adjuvant therapy in high-risk retinoblastoma. Arch Ophthalmol 2002; 120:923-931. (Pubitemid 34755545)
15. Eagle RC Jr. High-risk features and tumor differentiation in retinoblastoma: a retrospective histopathologic study. Arch Pathol Lab Med 2009; 133:1203-1209.
16. Kaliki S, Shields CL, Shah SU, et al. Postenucleation adjuvant chemotherapy with vincristine, etoposide and carboplatin for the treatment of high-risk retinoblastoma. Arch Ophthalmol 2011; 129:1422-1427. In 52 eyes with high-risk retinoblastoma, vincristine, etoposide, and carboplatin prevented metastasis in 100% of cases.
17. Shields CL, Shields JA. Intra-arterial chemotherapy for retinoblastoma: the beginning of a long journey (Editorial). Clin Exp Ophthalmol 2010; 38:638-643. Trends in the management of retinoblastoma indicates that each treatment has benefits and risks. Intra-arterial chemotherapy should be used with caution.
18. Kingston JE, Hungerford JL, Madreperla SA, Plowman PN. Results of combined chemotherapy and radiotherapy for advanced intraocular retinoblastoma. Arch Ophthalmol 1996; 114:1339-1343. (Pubitemid 26398719)
19. Gallie BL, Budning A, DeBoer G, et al. Chemotherapy with focal therapy can cure intraocular retinoblastoma without radiotherapy. Arch Ophthalmol 1996; 114:1321-1328. (Pubitemid 26398717)
20. Murphree AL, Villablanca JG, Deegan WF 3rd, et al. Chemotherapy plus local treatment in the management of intraocular retinoblastoma. Arch Ophthalmol 1996; 114:1348-1356. (Pubitemid 26398720)
21. Shields CL, De Potter P, Himelstein BP, et al. Chemoreduction in the initial management of intraocular retinoblastoma. Arch Ophthalmol 1996; 114:1330-1338. (Pubitemid 26398718)
22. Shields CL, Honavar SG, Meadows AT, et al. Chemoreduction plus focal therapy for retinoblastoma: factors predictive of need for treatment with external beam radiotherapy or enucleation. Am J Ophthalmol 2002; 133:657-664. (Pubitemid 34462014)
23. Shields CL, Shields JA. Chemotherapy for retinoblastoma (Editorial). Med Ped Oncol 2002; 38:377-378. (Pubitemid 34507279)
24. Shields CL, Shields JA. Changing management of retinoblastoma (Editorial). Clin Exp Ophthalmol 2004; 32:345-346. (Pubitemid 39193847)
25. Shields JA, Shields CL, Meadows AT. Chemoreduction in the management of retinoblastoma (Editorial). Am J Ophthalmol 2005; 140:505-506. (Pubitemid 41224843)
26. Shields CL, Honavar SG, Shields JA, et al. Factors predictive of recurrence of retinal tumor, vitreous seeds and subretinal seeds following chemoreduction for retinoblastoma. Arch Ophthalmol 2002; 120:460-464. (Pubitemid 34727817)
27. Shields CL, Mashayekhi A, Cater J, et al. Chemoreduction for retinoblastoma: analysis of tumor control and risks for recurrence in 457 tumors. Am J Ophthalmol 2004; 138:329-337. (Pubitemid 39208559)
28. Gombos DS, Kelly A, Coen PG, et al. Retinoblastoma treated with primary chemotherapy alone: the significance of tumor size, location and age. Br J Ophthalmol 2002; 86:80-83. (Pubitemid 34074890)
29. Schefler AC, Cicciarelli N, Feuer W, et al. Macular retinoblastoma: evaluation of tumor control, local complications, and visual outcomes for eyes treated with chemotherapy and repetitive foveal laser ablation. Ophthalmology 2007; 114:162-169. (Pubitemid 46014287)
30. Shields CL, Mashayekhi A, Au AK, et al. The International Classification of Retinoblastoma predicts chemoreduction success. Ophthalmology 2006; 113:2276-2280. (Pubitemid 44838917)
31. Shields CL, Ramasubramanian A, Thangappan A, et al. Chemoreduction (CRD) for group E retinoblastoma. Comparison of CRD alone versus CRD plus low dose external radiotherapy in 76 eyes. Ophthalmology 2009; 117:544-551.
32. Shields CL, Palamar M, Sharma P, et al. Retinoblastoma regression patterns following chemoreduction and adjuvant therapy in 557 tumors. Arch Ophthalmol 2009; 127:282-290.
33. Shields CL, Meadows AT, Shields JA, et al. Chemoreduction for retinoblastoma may prevent intracranial neuroblastic malignancy (trilateral retinoblastoma). Arch Ophthalmol 2001; 119:1269-1272.
34. Moll AC, Imhof SM, Schouten-Van Meeteren AY, et al. Chemoreduction for retinoblastoma. Arch Ophthalmol 2003; 121:1513. (Pubitemid 37243769)
35. Turaka K, Shields CL, Leahey A, Meadows AT. Second malignant neoplasms following chemoreduction for retinoblastoma in 272 patients. Pediatr Blood Cancer 2011. doi: 10.1002/pbc.23278 [Epub ahead of print]. In an analysis of 245 children with retinoblastoma that were treated with chemoreduction and followed long-term, there was no second malignant neoplasm in any patient treated with chemotherapy alone by mean 11 years follow-up.
36. Yamane T, Kaneko A, Mohri M. The technique of ophthalmic arterial infusion therapy for patients with intraocular retinoblastoma. Int J Clin Oncol 2004; 9:69-73. (Pubitemid 38619319)
37. Abramson DH, Dunkel IJ, Brodie SE, et al. A Phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results. Ophthalmology 2008; 115:1398-1404.
38. Shields CL, Ramasubramanian A, Rosenwasser R, Shields JA. Superselective catheterization of the ophthalmic artery for intraarterial chemotherapy for retinoblastoma. Retina 2009; 29:1207-1209.
39. Lin P, O'Brien JM. Frontiers in the management of retinoblastoma. Am J Ophthalmol 2009; 148:192-198.
40. Vajzovic LM, Murray TG, Aziz-Sultan MA, et al. Supraselective intra-arterial chemotherapy: evaluation of treatment-related complications in advanced retinoblastoma. Clin Ophthalmol 2011; 5:171-176.
41. Peterson EC, Elhammady MS, Quintero-Wolfe S, et al. Selective ophthalmic artery infusion of chemotherapy for advanced intraocular retinoblastoma: initial experience with 17 tumors. J Neurosurg 2011; 114:1603-1608.
42. Shields CL, Bianciotto CG, Ramasubramanian A, et al. Intra-arterial chemotherapy for retinoblastoma. Report #1: control of tumor, subretinal seeds, and vitreous seeds. Arch Ophthalmol 2011; 129:1399-1406. Intra-arterial chemotherapy provided 100% tumor control for groups C and D retinoblastoma and 33% control for group E.
43. Shields CL, Bianciotto CG, Jabbour P, et al. Intra-arterial chemotherapy for retinoblastoma. Report #2: treatment complications. Arch Ophthalmol 2011; 129:1407-1415. Intra-arterial chemotherapy was associated with ophthalmic ischemic events in the ophthalmic, retinal, and choroidal circulation, occasionally leading to related vision loss.
44. Eagle RC Jr, Shields CL, Bianciotto CG, et al. Histopathologic observations after intra-arterial chemotherapy for retinoblastoma. Arch Ophthalmol 2011; 129:1416-1421. In eight patients treated at centers in the USA, birefringent material with occluded vessels were noted in five cases, perhaps representing chemotherapy precipitate, cotton fibers, or other contaminants.
45. Wilson MW, Jackson JS, Phillips BX, et al. Real-time ophthalmoscopic findings of superselective intraophthalmic artery chemotherapy in a nonhuman primate model. Arch Ophthalmol 2011; 129:1458-1465. In a nonhuman study of six monkeys treated with intra-arterial chemotherapy with 18 sessions, 100% showed retinal artery narrowing, retinal edema, and choroidal blanching during the procedure.
46. Abramson D. Chemosurgery for retinoblastoma. What we know after 5 years. Arch Ophthalmol 2011; 129:1492-1493. In this editorial on intra-arterial chemotherapy, the author focuses on the successful ability to catheterize the tiny ophthalmic artery in most cases and the ability to save eyes that would have otherwise been enucleated.
47. Wilson MW, Haik BG, Dyer MA. Superselective intraophthalmic artery chemotherapy. What we do not know. Arch Ophthalmol 2011; 129:1490-1491. In this editorial on intra-arterial chemotherapy, the authors focus on the pharmacokinetics of melphalan, a dangerous chemotherapy agent. They indicate that further study on the effects of this drug on the eye and the body is appropriate.
48. Levin MH, Gombos DS, O'Brien JM. Intra-arterial chemotherapy for advanced retinoblastoma. Is the time right for a prospective clinical trial? Arch Ophthalmol 2011; 129:1487-1489. In this editorial on intra-arterial chemotherapy, the authors commend previous publications regarding success and toxicity of this technique, but believe that a collaborative prospective trial on this new method is warranted.
49. Albert DM. Editor's note. Arch Ophthalmol 2011; 129:1487. In this note, the editor of a major ophthalmic journal identifies the disparate editorial opinions on a single technique.
50. Suzuki S, Yamane T, Mohri M, Kaneko A. Selective ophthalmic arterial injection therapy for intraocular retinoblastoma: the long-term prognosis. Ophthalmology 2011; 118:2081-2087. Using the Japanese technique of balloon occlusion of the internal carotid artery for chemotherapy delivery in 343 patients, tumor control was 100% group A, 88% group B, 65% group C, 45% group D, and 30% group E. Complications were few.
51. Bianciotto CG, Shields CL, Iturralde JC, et al. Fluorescein angiographic findings after intra-arterial chemotherapy for retinoblastoma. Ophthalmology 2011. [Epub ahead of print] Fluorescein angiography following intra-arterial chemotherapy showed subclinical retinal vascular pruning in several cases.
52. Shields CL, Kaliki S, Shah SU, et al. Effect of intra-arterial chemotherapy on retinoblastoma-induced retinal detachment 2011 [Epub ahead of print]. Following intra-arterial chemotherapy for retinoblastoma, subtotal retinal detachment resolved in 100% cases and total retinal detachment resolved completely in 43% and partially in 57%.
53. Ferris FL, Chew EY. A new era for the treatment of retinoblastoma. Arch Ophthalmol 1996; 114:1412.
54. Friedman DL, Himelstein B, Shields CL, et al. Chemoreduction and local ophthalmic therapy for intraocular retinoblastoma. J Clin Oncol 2000; 18:12-17. (Pubitemid 30036331)
55. Lambert MP, Shields CL, Meadows AT. A retrospective review of hearing in children with retinoblastoma treated with carboplatin-based chemotherapy. Pediatr Blood Cancer 2008; 50:223-226.
56. Qaddoumi I, Bass JK, Wu J, et al. Carboplatin associated ototoxicity in children with retinoblastoma. J Clin Oncol 2012 (in press).
57. Leahey A. A cautionary tale: dosing chemotherapy in infants with retinoblastoma. J Clin Oncol 2012 (in press).
58. Friedrich MJ. Retinoblastoma therapy delivers power of chemotherapy with surgical precision. J Am Med Assoc 2011; 305:2276-2278.
59. Shields CL, Shields JA, Meadows AT. Chemoreduction for retinoblastoma may prevent trilateral retinoblastoma [letter]. J Clin Oncol 2000; 18:236-237.
60. Gombos DS, Hungerford J, Abramson DH, et al. Secondary acute myelogenous leukemia in patients with retinoblastoma. Is chemotherapy a factor? Ophthalmology 2007; 114:1378-1383. (Pubitemid 47008929)
61. Rihani R, Bazzeh F, Faqih N, et al. Secondary hematopoietic malignancies in survivors of childhood cancer: an analysis of 111 cases from the Surveillance, Epidemiology, and End Result-9 registry. Cancer 2010; 116:4385-4394.
62. Wong FL, Boice JD Jr, Abramson DH, et al. Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. J Am Med Assoc 1997; 278:1262-1267. (Pubitemid 27435614)
63. Kleinerman FA, Tucker MA, Abramson DH, et al. Risk for soft tissue sarcomas by individual subtype in survivors of hereditary retinoblastoma. J Natl Cancer Inst 2007; 99:24-31.
64. Marees T, Moll AC, Imhof SM, et al. Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up. J Natl Cancer Inst 2008; 100:1771-1779.
65. Shields CL, Kaliki S, Shah SU, et al. Minimal exposure (1 or 2 cycles) of intra-arterial chemotherapy in the management of retinoblastoma. Ophthalmology 2011 [Epub ahead of print]. In a group of eight patients treated with only one or two cycles of intra-arterial chemotherapy, tumor control was complete in 88% and partial in 12%.